Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

Daisuke Ennishi, H. Asai, Yoshinobu Maeda, K. Shinagawa, K. Ikeda, M. Yokoyama, Y. Terui, K. Takeuchi, Tadashi Yoshino, K. Matsuo, K. Hatake, M. Tanimoto

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins. Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis. Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.

Original languageEnglish
Pages (from-to)1217-1221
Number of pages5
JournalAnnals of Oncology
Volume21
Issue number6
DOIs
Publication statusPublished - Nov 2 2009

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Survival Rate
Rituximab
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Retrospective Studies
Cholesterol
Drug Therapy

Keywords

  • Diffuse large B-cell lymphoma
  • Rituximab
  • Statin

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. / Ennishi, Daisuke; Asai, H.; Maeda, Yoshinobu; Shinagawa, K.; Ikeda, K.; Yokoyama, M.; Terui, Y.; Takeuchi, K.; Yoshino, Tadashi; Matsuo, K.; Hatake, K.; Tanimoto, M.

In: Annals of Oncology, Vol. 21, No. 6, 02.11.2009, p. 1217-1221.

Research output: Contribution to journalArticle

Ennishi, D, Asai, H, Maeda, Y, Shinagawa, K, Ikeda, K, Yokoyama, M, Terui, Y, Takeuchi, K, Yoshino, T, Matsuo, K, Hatake, K & Tanimoto, M 2009, 'Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy', Annals of Oncology, vol. 21, no. 6, pp. 1217-1221. https://doi.org/10.1093/annonc/mdp490
Ennishi, Daisuke ; Asai, H. ; Maeda, Yoshinobu ; Shinagawa, K. ; Ikeda, K. ; Yokoyama, M. ; Terui, Y. ; Takeuchi, K. ; Yoshino, Tadashi ; Matsuo, K. ; Hatake, K. ; Tanimoto, M. / Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. In: Annals of Oncology. 2009 ; Vol. 21, No. 6. pp. 1217-1221.
@article{971137f5404246b1823ab380bd8c8546,
title = "Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy",
abstract = "Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins. Results: The 3-year progression-free survival rates were 84{\%} and 73{\%} (P = 0.38), while the overall survival rates were 89{\%} and 78{\%} (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis. Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.",
keywords = "Diffuse large B-cell lymphoma, Rituximab, Statin",
author = "Daisuke Ennishi and H. Asai and Yoshinobu Maeda and K. Shinagawa and K. Ikeda and M. Yokoyama and Y. Terui and K. Takeuchi and Tadashi Yoshino and K. Matsuo and K. Hatake and M. Tanimoto",
year = "2009",
month = "11",
day = "2",
doi = "10.1093/annonc/mdp490",
language = "English",
volume = "21",
pages = "1217--1221",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy

AU - Ennishi, Daisuke

AU - Asai, H.

AU - Maeda, Yoshinobu

AU - Shinagawa, K.

AU - Ikeda, K.

AU - Yokoyama, M.

AU - Terui, Y.

AU - Takeuchi, K.

AU - Yoshino, Tadashi

AU - Matsuo, K.

AU - Hatake, K.

AU - Tanimoto, M.

PY - 2009/11/2

Y1 - 2009/11/2

N2 - Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins. Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis. Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.

AB - Background: A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. Patients and methods: We conducted a retrospective study investigating the effects of statins on the prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Newly diagnosed DLBCL patients were analyzed (n = 256), including 35 patients taking statins. Results: The 3-year progression-free survival rates were 84% and 73% (P = 0.38), while the overall survival rates were 89% and 78% (P = 0.28) for those patients treated with and without statins, respectively. After adjusting for the International Prognostic Index and serum cholesterol level, statin use was not associated with prognosis. Conclusions: These results indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Further studies with larger numbers of patients are warranted to confirm the prognostic significance of statins for patients with DLBCL receiving rituximab-containing chemotherapy.

KW - Diffuse large B-cell lymphoma

KW - Rituximab

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=77954024437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954024437&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp490

DO - 10.1093/annonc/mdp490

M3 - Article

C2 - 19884246

AN - SCOPUS:77954024437

VL - 21

SP - 1217

EP - 1221

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -